Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers?
Key takeaways
- Reuben Gregg Brewer, The Motley Fool Sat, May 9, 2026 at 11:35 PM GMT+7 3 min read PFE Pfizer (NYSE: PFE) is in a difficult spot right now.
- As the short list of problems above highlights, Pfizer is not hitting on all cylinders right now.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
Reuben Gregg Brewer, The Motley Fool Sat, May 9, 2026 at 11:35 PM GMT+7 3 min read PFE Pfizer (NYSE: PFE) is in a difficult spot right now. It has a number of blockbuster drugs nearing the end of their patent protection, which will likely lead to material revenue declines. It has fallen behind in the GLP-1 weight-loss drug race. And its payout ratio is worryingly high. Here s why you might want to buy it anyway.
As the short list of problems above highlights, Pfizer is not hitting on all cylinders right now. Wall Street knows this, which helps explain why the pharmaceutical company s stock has fallen more than 50% from its 2021 highs. To be fair, that high was partly driven by over-enthusiastic investors, who priced in years of COVID vaccine revenues that didn t materialize. But given the company s long and successful history, investors still seem overly pessimistic about Pfizer s future.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »